Patents by Inventor Andras Gruber
Andras Gruber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230340501Abstract: The present invention provides methods of producing thrombin using coordinated coexpression systems, and particularly inducible coexpression systems, capable of controlled induction of expression of each gene product required for the production of thrombin.Type: ApplicationFiled: May 1, 2023Publication date: October 26, 2023Inventors: Sean McClain, Mark Valasek, Andras Gruber
-
Publication number: 20220089777Abstract: Novel binding molecules, comprising humanized antibodies, fragments, variants, and derivatives thereof, compositions, methods, and kits comprising the same, are described, wherein the binding molecules specifically bind to FXI and FXIa. The binding molecules are capable of binding to and forming an immune complex with the factor XI A2 domain, and thereby disrupting the contact activation molecular complex without affecting hemostatic factor XI activity or activation. The binding molecule of this disclosure is useful in safely inhibiting thrombosis and inflammation without compromising hemostasis. The binding molecules, compositions, methods, and kits provided herein are therefore intended to treat, inter alia, thrombosis- and inflammation-related diseases and conditions. Moreover, polynucleotides encoding the binding molecules of this disclosure, vectors comprising the polynucleotides, and host cells for producing the polynucleotides are provided.Type: ApplicationFiled: January 20, 2020Publication date: March 24, 2022Inventors: Andras Gruber, Erik I Tucker, Christina U Lorentz
-
Publication number: 20220089776Abstract: Monoclonal antibodies that bind, such as specifically bind, blood protein factor XII (FXII) are described. The monoclonal antibodies (including antigen-binding fragments thereof) are capable of forming immune complexes with human FXII and inhibiting FXII activity, resulting in safe anti-inflammatory and anti-thrombotic effects.Type: ApplicationFiled: November 27, 2019Publication date: March 24, 2022Applicants: Oregon Health & Science University, Aronora, Inc.Inventors: Michael Wallisch, Andras Gruber, Erik I. Tucker, Christina U. Lorentz
-
Publication number: 20210275569Abstract: Provided herein are methods, compounds, and compositions for safely reducing thrombopoietin in a cell or an individual. Such methods, compounds, and compositions maintain platelet count within a safe hemostatic range. Such methods, compounds, and compositions are useful to safely treat, prevent, or ameliorate a disease that can benefit from platelet count reduction in an individual. Such methods, compounds, and compositions are useful for treating or preventing diseases in which thrombopoietin contributes to the presence or activation of platelets contributes to and promotes disease initiation or progression, and/or adversely affects disease outcome.Type: ApplicationFiled: July 16, 2019Publication date: September 9, 2021Applicants: Aronora, Inc., Oregon Health & Science University, Ionis Pharmaceuticals, Inc.Inventors: Andras Gruber, Erik Tucker, Brett P. Monia, Alexey Revenko
-
Patent number: 10577428Abstract: Compositions and methods for inhibiting thrombosis without compromising hemostasis are described. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The disclosure further includes pharmaceutical compositions comprising the disclosed anti-factor XI monoclonal antibodies, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.Type: GrantFiled: July 30, 2018Date of Patent: March 3, 2020Assignees: Oregon Health & Science University, Vanderbilt UniversityInventors: Andras Gruber, Erik I. Tucker, Stephen Raymond Hanson, David Gailani
-
Publication number: 20200063116Abstract: The present invention provides methods of producing thrombin using coordinated coexpression systems, and particularly inducible coexpression systems, capable of controlled induction of expression of each gene product required for the production of thrombin.Type: ApplicationFiled: November 5, 2019Publication date: February 27, 2020Inventors: Sean McClain, Mark Valasek, Andras Gruber
-
Patent number: 10508270Abstract: The present invention provides methods of producing thrombin using coordinated coexpression systems, and particularly inducible coexpression systems, capable of controlled induction of expression of each gene product required for the production of thrombin, and the thrombin produced by this method.Type: GrantFiled: February 5, 2014Date of Patent: December 17, 2019Assignees: AbSci LLC, Aronora Inc.Inventors: Sean McClain, Mark Valasek, Andras Gruber
-
Publication number: 20180355057Abstract: Compositions and methods for inhibiting thrombosis without compromising hemostasis are described. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The disclosure further includes pharmaceutical compositions comprising the disclosed anti-factor XI monoclonal antibodies, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.Type: ApplicationFiled: July 30, 2018Publication date: December 13, 2018Applicants: Oregon Health & Science University, Vanderbilt UniversityInventors: Andras Gruber, Erik I. Tucker, Stephen Raymond Hanson, David Gailani
-
Publication number: 20170204195Abstract: Compositions and methods for inhibiting thrombosis without compromising hemostasis are described. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The disclosure further includes pharmaceutical compositions comprising the disclosed anti-factor XI monoclonal antibodies, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.Type: ApplicationFiled: March 27, 2017Publication date: July 20, 2017Applicants: Oregon Health & Science University, Vanderbilt UniversityInventors: Andras Gruber, Erik I. Tucker, Stephen Raymond Hanson, David Gailani
-
Patent number: 9636399Abstract: Compositions and methods for inhibiting thrombosis without compromising hemostasis are described. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The disclosure further includes pharmaceutical compositions comprising the disclosed anti-factor XI monoclonal antibodies, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.Type: GrantFiled: July 27, 2015Date of Patent: May 2, 2017Assignees: Oregon Health & Science University, Vanderbilt UniversityInventors: Andras Gruber, Erik I. Tucker, Stephen Raymond Hanson, David Gailani
-
Patent number: 9637550Abstract: Disclosed herein are monoclonal antibodies specific for factor XI (fXI) that prevent activation of fXI by factor XIIa (fXIIa). The monoclonal antibodies are universal fXI antibodies, capable of binding all mammalian species tested. The anti-fXI monoclonal antibodies prolong clotting time in mammalian plasmas. Moreover, administration of the fXI monoclonal antibodies disclosed herein results in inhibition of thrombosis without altering hemostasis in animal models of thrombosis. Thus, provided herein are monoclonal antibodies specific for fXI that block activation of fXI by fXIIa, compositions and immunoconjugates comprising such antibodies and their methods of use.Type: GrantFiled: December 12, 2014Date of Patent: May 2, 2017Assignees: Oregon Health & Science University, Vanderbilt UniversityInventors: Andras Gruber, Erik I. Tucker, David Gailani
-
Patent number: 9574013Abstract: Provided are antibodies that selectively bind to and inhibit activation of coagulation factor XII. Methods of treatment employing these antibodies are described herein.Type: GrantFiled: December 6, 2013Date of Patent: February 21, 2017Assignees: VANDERBILT UNIVERSITY, ARONORA, INC., OREGON HEALTH & SCIENCE UNIVERSITYInventors: Andras Gruber, David Gailani, Philberta Leung, Anton Matafonov
-
Publication number: 20160160203Abstract: The present invention provides methods of producing thrombin using coordinated coexpression systems, and particularly inducible coexpression systems, capable of controlled induction of expression of each gene product required for the production of thrombin, and the thrombin produced by this method.Type: ApplicationFiled: February 5, 2014Publication date: June 9, 2016Inventors: Sean McClain, Mark Valasek, Andras Gruber
-
Publication number: 20150322163Abstract: Compositions and methods for inhibiting thrombosis without compromising hemostasis are described. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The disclosure further includes pharmaceutical compositions comprising the disclosed anti-factor XI monoclonal antibodies, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.Type: ApplicationFiled: July 27, 2015Publication date: November 12, 2015Applicants: VANDERBILT UNIVERSITY, OREGON HEALTH & SCIENCE UNIVERSITYInventors: Andras Gruber, Erik I. Tucker, Stephen Raymond Hanson, David Gailani
-
Publication number: 20150315292Abstract: Provided are antibodies that selectively bind to and inhibit activation of coagulation factor XII. Methods of treatment employing these antibodies are described herein.Type: ApplicationFiled: December 6, 2013Publication date: November 5, 2015Inventors: Andras GRUBER, David GAILANI, Philberta LEUNG, Anton MATAFONOV
-
Patent number: 9125895Abstract: The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.Type: GrantFiled: April 1, 2014Date of Patent: September 8, 2015Assignees: Oregon Health & Science University, Vanderbilt UniversityInventors: Andras Gruber, Erik I. Tucker, Stephen Raymond Hanson, David Gailani
-
Publication number: 20150093395Abstract: Disclosed herein are monoclonal antibodies specific for factor XI (fXI) that prevent activation of fXI by factor XIIa (fXIIa). The monoclonal antibodies are universal fXI antibodies, capable of binding all mammalian species tested. The anti-fXI monoclonal antibodies prolong clotting time in mammalian plasmas. Moreover, administration of the fXI monoclonal antibodies disclosed herein results in inhibition of thrombosis without altering hemostasis in animal models of thrombosis. Thus, provided herein are monoclonal antibodies specific for fXI that block activation of fXI by fXIIa, compositions and immunoconjugates comprising such antibodies and their methods of use.Type: ApplicationFiled: December 12, 2014Publication date: April 2, 2015Applicants: VANDERBILT UNIVERSITY, OREGON HEALTH & SCIENCE UNIVERSITYInventors: Andras Gruber, Erik I. Tucker, David Gailani
-
Patent number: 8940297Abstract: One aspect of the invention contemplates a mutant E-WE thrombin precursor that contains the SEQ ID NO:1 amino acid residue sequence. Another aspect contemplates a thrombin precursor that contains the amino acid residue sequence Asp/Glu-Gly-Arg at positions 325, 326 and 327 based on the preprothrombin sequence. A third aspect contemplates a thrombin precursor that contains the SEQ ID NO:1 amino acid residue sequence as well as the amino acid residue sequence Asp/Glu Gly Arg at positions 325, 326 and 327 based on the preprothrombin sequence. Also contemplated is a composition that contains an effective amount of mutant thrombin dissolved or dispersed in a pharmaceutically acceptable carrier. A method is also disclosed for enhancing treating and preventing thrombosis in a mammal in need using that composition.Type: GrantFiled: December 20, 2011Date of Patent: January 27, 2015Assignee: Saint Louis UniversityInventors: Enrico Di Cera, Andras Gruber, Prafull Gandhi, Leslie Pelc, Nicola Pozzi, David Collier Wood
-
Patent number: 8940883Abstract: Disclosed herein are monoclonal antibodies specific for factor XI (fXI) that prevent activation of fXI by factor XIIa (fXIIa). The monoclonal antibodies are universal fXI antibodies, capable of binding all mammalian species tested. The anti-fXI monoclonal antibodies prolong clotting time in mammalian plasmas. Moreover, administration of the fXI monoclonal antibodies disclosed herein results in inhibition of thrombosis without altering hemostasis in animal models of thrombosis. Thus, provided herein are monoclonal antibodies specific for fXI that block activation of fXI by fXIIa, compositions and immunoconjugates comprising such antibodies and their methods of use.Type: GrantFiled: January 31, 2013Date of Patent: January 27, 2015Assignees: Oregon Health & Science University, Vanderbilt UniversityInventors: Andras Gruber, Erik I. Tucker, David Gailani
-
Publication number: 20140322219Abstract: The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.Type: ApplicationFiled: April 1, 2014Publication date: October 30, 2014Applicants: Vanderbilt University, Oregon Health & Science UniversityInventors: Andras Gruber, Erik I. Tucker, Stephen Raymond Hanson, David Gailani